HIROTSU BIO SCIENCE Co., Ltd. (Headquarters: Chiyoda-ku, Tokyo; CEO: Takasuke Hirotsu; hereinafter referred to as "the Company") is pleased to announce that it has reached its 10th anniversary since the development of the nematode cancer risk test "N-NOSE®" and has surpassed a cumulative total of 1 million samples. To commemorate this milestone, we will fully implement our proprietary AI image analysis technology, which utilizes the nematode's chemotaxis data accumulated from 1 million samples, into our testing process starting July 1, 2026. Furthermore, to express our gratitude to all those who have used N-NOSE® and to provide an opportunity for more people to become interested in their health status, we will be holding the "N-NOSE® 10th Anniversary x 1 Million Samples Double Commemorative Campaign" starting on Wednesday, July 1, 2026. ■ Milestone of N-NOSE® 10th Anniversary and 1 Million Cumulative Samples N-NOSE®, for which research and development began in 2016, has been developed with the aim of "making it easier for everyone to know their health status" by focusing on the superior olfactory capabilities of nematodes. We interpret surpassing 1 million cumulative samples as a result of many people taking an interest in their health and choosing N-NOSE® as the first step towards healthy behavior. Moreover, the data asset of 1 million samples serves as a crucial foundation to support future research and development and the advancement of our testing process. ■ Full Implementation of AI Analysis Utilizing Big Data from 1 Million Samples Starting July 1, 2026, the Company will fully implement its proprietary AI image analysis technology, which utilizes the accumulated nematode chemotaxis data, into its testing process. By leveraging AI technology, we aim to improve the efficiency of analyzing vast amounts of data and further optimize the testing process, thereby establishing a stable service provision system. We will continue to advance our research and development